KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 54 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,504,000 | -37.8% | 143,000 | -8.5% | 0.00% | -50.0% |
| Q4 2020 | $2,418,000 | +4.0% | 156,227 | -1.9% | 0.00% | 0.0% |
| Q3 2020 | $2,325,000 | -21.7% | 159,227 | +1.6% | 0.00% | -33.3% |
| Q2 2020 | $2,969,000 | +16.3% | 156,782 | +18.0% | 0.00% | 0.0% |
| Q1 2020 | $2,553,000 | -56.3% | 132,897 | -56.4% | 0.00% | -40.0% |
| Q4 2019 | $5,846,000 | +234.8% | 304,940 | +68.0% | 0.01% | +150.0% |
| Q3 2019 | $1,746,000 | +82.1% | 181,500 | +13.4% | 0.00% | +100.0% |
| Q2 2019 | $959,000 | -0.9% | 160,100 | -3.4% | 0.00% | 0.0% |
| Q1 2019 | $968,000 | -37.7% | 165,746 | 0.0% | 0.00% | -50.0% |
| Q4 2018 | $1,553,000 | +170.1% | 165,746 | +391.0% | 0.00% | +100.0% |
| Q3 2018 | $575,000 | +69.6% | 33,760 | +69.0% | 0.00% | – |
| Q2 2018 | $339,000 | +45.5% | 19,971 | +299.4% | 0.00% | – |
| Q2 2014 | $233,000 | +108.0% | 5,000 | 0.0% | 0.00% | – |
| Q4 2013 | $112,000 | – | 5,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 3,561,052 | $26,245,000 | 5.86% |
| Palo Alto Investors LP | 5,621,533 | $41,431,000 | 3.20% |
| Iron Triangle Partners LP | 2,000,000 | $14,740,000 | 1.75% |
| Altium Capital Management LP | 645,000 | $4,754,000 | 1.59% |
| Birchview Capital, LP | 269,332 | $1,985,000 | 1.43% |
| Rubric Capital Management LP | 3,607,443 | $26,587,000 | 0.96% |
| Lombard Odier Asset Management (Switzerland) SA | 776,053 | $5,720,000 | 0.45% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,344,929 | $9,912,000 | 0.40% |
| Golden State Equity Partners | 41,850 | $308,000 | 0.16% |
| Hennion & Walsh Asset Management, Inc. | 385,837 | $2,844,000 | 0.15% |